Objectives: Protamines are cationic peptides that exert antimicrobial activity. We have examined the evolution of bacterial resistance to protamine sulphate and the resulting effects on fitness and physiology, with the objective of increasing knowledge about mechanisms of bacterial resistance to antimicrobial peptides.
Introduction
Antimicrobial peptides (AMPs) are molecules involved in innate immunity and are found in organisms ranging from bacteria to man. These peptides have killing activity against many microbes, but are also involved in several additional immune reactions including wound healing, recruitment of leucocytes and modulation of the inflammatory response. 1, 2 As antibiotic-resistant bacteria have increased in prevalence the need for alternative treatments has become more important, making AMPs potential candidates as antibacterial drugs. However, little is known about the consequences of clinical AMP usage with regard to resistance development. For example, concerns have been raised that widespread pharmaceutical use of AMPs could select for microbes that are not only resistant to the peptide in question, but that can also evade the normal repertoire of AMPs in the human body. 3 AMPs are generally sensitive to environmental conditions (e.g. agar, salt and cation concentrations) and are therefore often inactivated in standard laboratory media, making it difficult and expensive to perform agar plate-based genetic studies of resistance. 4 -6 In contrast, protamine from salmon sperm cells is a highly cationic and basic peptide that has been used as a cheap and active model peptide in several studies substituting for more expensive or easily inactivated AMPs. Although lacking the typical amphiphilic amino acid composition of many AMPs, protamine is still capable of killing a variety of different microorganisms. 7 -11 Groisman et al. 12 screened a library of transposon insertions in Salmonella enterica serovar Typhimurium (i.e. Salmonella Typhimurium) 14028s for hypersusceptibility to protamine, and identified several genes important for bacterial defence against AMPs. Dhawan et al. 6 used protamine sulphate resistance as a surrogate marker when selecting bacterial mutants with increased resistance to thrombin-induced platelet microbicidal protein (tPMP-1), and protamine has subsequently been used in several studies of tPMP-1. 13 -15 Sadowska et al. 16 used protamine as a model to study the cationic peptides encountered by Staphylococcus aureus in the human body. They observed that subinhibitory concentrations of protamine selected for small colony variants (SCVs) of S. aureus. SCVs are mutant subpopulations of bacteria that differ in many aspects from their parental counterparts. Typical characteristics include slow growth, aminoglycoside resistance, lack of pigmentation and inability to use many carbon sources. 17 Several bacterial species are known to form SCVs, and these cells are often involved in recurrent and persistent infections and are very resilient to antibiotic treatment. 17 -19 It has been suggested that the ability to form SCVs is important for the disease progression of intracellular pathogens such as Salmonella and that the SCV phenotype may be selected by cationic peptides present in the body. 16, 17, 20 The SCV phenotype could be a way for bacteria to improve intracellular persistence and avoid killing by host defences.
In this study, we examined the mechanism and rate of formation of mutations conferring decreased susceptibility to protamine sulphate in Salmonella Typhimurium LT2, with the objective of increasing knowledge about different bacterial resistance mechanisms towards AMPs. We report that spontaneous, protamine-resistant mutants arise at a comparatively high rate and that most of these mutants had the typical characteristics of SCVs, such as slow growth and aminoglycoside resistance. A variety of resistance-associated mutations were identified in genes whose products are involved in electron transport and respiration. When the selective pressure was removed, some of the mutants quickly re-established fast growth and lost the resistance phenotype, while others were stable for several hundred generations of growth.
Materials and methods

Bacterial strains, media and growth conditions
The strains used in this study are derivatives of Salmonella Typhimurium LT2, and are listed in Table 1 . Unless indicated, bacteria were grown at 378C in Iso-Sensitest broth (Oxoid Ltd, Hampshire, UK) supplemented with 0.2% glucose. For solid media, LE SeaKem agarose (Lonza, Rockland, ME, USA) was added to a final concentration of 1%. Luria-Bertani broth (LB) and agar (LA) were used when indicated. Protamine sulphate, colistin, chloramphenicol, streptomycin and tetracycline were added to the growth medium when appropriate (all from Sigma-Aldrich, St Louis, MO, USA). Martin Malmsten (Uppsala University, Uppsala, Sweden), Mikael Rhen, Birgitta Agerberth and Katrin Pü tsep (all at Karolinska Institutet, Stockholm, Sweden) kindly provided CNY100 H-L, bleomycin, mCRAMP/rCRAMP and HNP-1, respectively. The peptides LL-37 and PR-39 were purchased from Innovagen (Lund, Sweden) and lactoferricin B (fragment 4-14) from Sigma-Aldrich.
PCR, sequencing and DNA isolation
Genes of interest were PCR amplified with AmpliTaq Gold polymerase in a GeneAmp PCR System 9700 (Applied Biosystems) using genomic DNA, bacterial colonies or 1 mL of an overnight culture as template. Genomic DNA was isolated using a Wizard Genomic DNA purification kit (Promega, Madison, WI, USA) or a Qiagen Genomic tip 100/G (Hilden, Germany). The PCR program used was as follows: 5 min of denaturation at 958C; and 31 cycles of 30 s at 948C, 30 s at the appropriate annealing temperature for each primer pair and elongation at 728C (1 min/kb). An additional 7 min elongation step was included after the final cycle. PCR products were purified from solution or 1% agarose gels using the Illustra GFX PCR DNA and gel band purification kit (GE Healthcare, Buckinghamshire, UK), lyophilized together with a sequencing primer and sent to Eurofins MWG Operon, Ebersberg, Germany, for sequencing. Primers used for amplification and sequencing can be found in Table S1 [available as Supplementary data at JAC Online (http://jac.oxfordjournals.org/)].
Isolation of mutants
Drops of 10 mL containing 4Â10 6 bacteria from independent cultures were placed on medium containing 300 mg/L protamine sulphate. The plates were incubated at 378C and examined over several days. Potential mutants (i.e. colonies appearing in the drop) were purified on LA plates. These clones were confirmed to have lower susceptibility by repeating the selection procedure. Only clones that survived the second exposure were included for further study. In total, 23 independent mutants were isolated.
Determination of the in vitro mutation rate to protamine resistance
To determine the mutation rate to protamine resistance, 4Â10
6 cfu from each of 75 independent Salmonella Typhimurium LT2 overnight cultures were spotted on plates supplemented with protamine sulphate at 300 mg/L. The number of colonies in each spot was scored over the next couple of days. The mutation rate was calculated by the p 0 method: 2[ln(p 0 /p tot )]/N, where p 0 is the number of cultures (i.e. spots) with no mutants, p tot is the total number of cultures and N is the number of bacteria applied in each spot. 21 
Growth rate measurements
An overnight culture of each strain to be tested was diluted to 10 5 -10 6 bacteria/mL and transferred in quadruplicate to a bioscreen plate (400 mL/well). Each strain was assayed in at least three separate experiments in a Bioscreen C Analyzer (Oy Growth Curves Ab Ltd, Helsinki, Finland) at 378C. Absorbance was measured at 600 nm every 4 min. The growth rate of the wild-type strain was set to 1 and the relative growth rate was calculated as t gen (wild-type)/t gen (mutant). The calculations were based on OD 600 values from 0.05 to 0.1 (protamine-resistant mutants) or 0.04 to 0.1 (compensated mutants).
Protamine susceptibility assay
MIC assays were performed in 10 mL glass tubes. Bacteria were grown to mid-exponential phase and diluted to 5Â10 5 cfu/mL. Bacterial suspension (800 mL) was mixed with 200 mL of protamine sulphate solution for final protamine concentrations of 2000, 1000, 500, 250, 125, 62.5 and 31.25 mg/L. The tubes were incubated at 378C without shaking for 18 h or 24-30 h for the wild-type and protamine-resistant mutants, respectively (due to the slow growth of the mutants), and the MIC was set to the lowest concentration of protamine sulphate yielding no visible growth. All experiments were done with duplicate samples on at least two separate occasions, and the average MIC was calculated. To further verify the resistance phenotype of the mutants, protamine susceptibility was also investigated by plate assays. Stationary-phase bacteria (varying Protamine resistance in Salmonella Typhimurium LT2 877 JAC between 100 and 10 7 cfu) were spotted and/or streaked on media containing different concentrations of protamine.
Genetic mapping of resistance mutations
Isolation of mini-Tn10 insertions P22 phage was grown on a pool of mini-Tn10s (D16D17, tetracycline resistant, TetR) inserted randomly in a wild-type genetic background. The resulting phage lysate was used to infect the slow-growing protamine-resistant strain of interest. Transductants were selected on LA plates supplemented with tetracycline (15 mg/L), and transposon insertions that restored the normal colony size phenotype were purified and saved. Linkage between the protamine resistance mutation (also assumed to be responsible for the slow growth phenotype) and the tetracycline marker was established by backcrosses into the original mutant. An isogenic pair of a tetracycline-resistant, fast-growing (protamine-susceptible) strain and a tetracycline-resistant, slow-growing (protamine-resistant) strain was saved at 2808C. The transposon insertions were also used in genetic linkage experiments to examine if any of the unmapped protamine-resistant mutants carried mutations in the same area.
Identification of insertion points
Arbitrarily primed PCRs were carried out to locate the transposon insertion points. In a first reaction, one transposon-specific primer was mixed with an array of arbitrary primers each comprising one variable part (15 bp) and one defined part (20 bp). The following PCR program was used: 5 min of denaturation at 958C; 5 cycles of 30 s at 948C, 30 s at 308C and 1 min at 728C; 30 cycles of 30 s at 948C, 30 s at 558C and 1 min at 728C; and a last elongation step of 5 min. The products from the first reaction then functioned as template in a second, nested PCR: 5 min of denaturation at 958C; and 29 cycles of 30 s at 948C, 30 s at 548C and 1 min at 728C, with the last elongation extended to 5 min. The PCR products were purified and sequenced using primers with homology to the transposon. Genes in the vicinity of the transposon were then PCR amplified and sequenced to identify the resistance mutations. 
Pränting and Andersson
Construction of haemin-permeable strains and a hemA/cysG double mutant P22 phage was grown on a strain with a hemA (V45G) mutation linked to a mini-Tn10 (identified from the mapping experiments above). The resulting lysate was used to transduce a haemin-permeable strain, carrying an env-53 mutation. 22 Transductants were selected on tetracycline and confirmed by colony PCR and sequencing. An isogenic pair of one haeminpermeable, protamine-susceptible (hem þ , fast-growing) strain and one haemin-permeable, protamine-resistant (hem 2 , slow-growing) strain was saved. A hemA (V45G)/cysG double mutant was constructed by moving a cysG1510::Tn10 (TetR) insertion into the hemA 2 background by transduction.
Aminolevulinic acid (ALA) and haemin complementation studies ALA and haemin (both from Sigma-Aldrich) were dissolved in water and 0.1 M NaOH and used at a final concentration of 50 and 10 mg/L, respectively. MIC assays with protamine in the presence of ALA or haemin were performed for the wild-type parental strain and a subset of the mutants as described above. Control experiments without ALA/haemin supplementation (but with identical protamine and NaOH concentrations) were run in parallel.
Cross-resistance studies
Susceptibility to antibiotics was determined using Etests (AB bioMérieux, Solna, Sweden). Bacteria, diluted to 10 7 cfu/mL, were spread with a cotton swab on Iso-Sensitest agar, after which the Etest was applied. Results were read after 16 h for the wild-type strain and after 24-40 h for the mutants. In addition, bacterial susceptibility was determined in time-kill assays with four antibiotics: tetracycline (3 mg/L); chloramphenicol (6 mg/L); streptomycin (8 mg/L); and colistin (1 mg/L). Bacteria were grown to mid-log phase and diluted to 5Â10 5 cfu/mL. A 5 mL aliquot of bacterial solution was transferred to 50 mL E-flasks after which antibiotic was added. One flask per strain was left untreated as a control. Samples were diluted and spread on LA plates to determine the viable count before addition of antibiotic and after 0.5, 1, 4 and 24 h. The experiment was performed three times for each strain and antibiotic, and survival was calculated as the number of viable cells at each timepoint divided by the number of cells at the start of the experiment.
Bleomycin is a glycopeptide antibiotic used in cancer therapy and CNY100 H-L is a synthetic peptide based on a fragment of C3a from the human complement system. 23, 24 LL-37, mCRAMP and rCRAMP are cathelicidin peptides that form pores in the bacterial membrane and are found in humans, mice and rats, respectively, while PR-39 is a porcine peptide that enters the bacterial cell and interferes with DNA and protein synthesis. 25 -28 Lactoferricin B is a bovine broad-spectrum AMP, while HNP-1 is a human a-defensin with in vitro activity against bacteria, fungi and viruses. 29, 30 The MICs of bleomycin and the AMPs CNY100 H-L, mCRAMP, rCRAMP, LL-37 and PR-39 were determined in Mueller-Hinton broth (Becton Dickinson and Company, Sparks, MD, USA) with 0.2% glucose in 96-well microtitre plates. Log-phase bacteria were diluted to 5Â10 5 cfu/mL and 45 or 90 mL was added to wells containing 5 or 10 mL of peptide solution, respectively. The MIC was set to the lowest concentration giving no visible growth after 18 h (wild-type) or 24-40 h (protamine-resistant mutants) of incubation at 378C. Bacterial susceptibility to lactoferricin B (4-14) and HNP-1 was determined in 10 mM sodium phosphate buffer supplemented with 0.03% trypticase soy broth (TSB; Becton Dickinson and Company). Log-phase bacteria were washed and diluted to 3Â10 6 cfu/mL, and 90 mL of bacterial solution was mixed with 10 mL of peptide solution in microcentrifuge tubes to give final concentrations of 0, 2.5, 5 or 10 mg/L (lactoferricin) and 0 or 100 mg/L (HNP-1). Samples (10 mL) were diluted and spread on LA after 0, 0.33, 1 and 3 h for viable counts (a 5 h timepoint was added for HNP-1).
Compensatory evolution
Compensatory evolution was carried out in LB supplemented with 0.2% glucose. Ten independent lineages were started for each strain and grown overnight. Every 24 h, the lineages were serially transferred with a population bottleneck of 10 6 bacteria into fresh medium. Each cycle corresponded to 7 -10 generations of growth, depending on the extent of growth of the mutant. Samples from all cultures were spread on LA plates every 1 -3 days and the plates were visually examined for growthcompensated strains (i.e. clones forming larger colonies than the ancestral mutant). When .50% of the colonies were large, one single fast-growing colony was picked and saved at 2808C. For a subset of the compensated mutants, exponential growth rates were measured and the genes carrying the original mutation were PCR amplified and sequenced.
Results
Isolation of mutants and determination of mutation rate
Twenty-three spontaneous, protamine-resistant Salmonella Typhimurium LT2 mutants were isolated and the mutation rate to protamine resistance was determined using the p 0 method. On average, 3.8Â10 6 cfu from 75 independent cultures were spotted on medium containing protamine sulphate. In 31 spots, no colonies appeared and the mutation rate was calculated to be 2.3Â10
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/cell/generation.
Identification of resistance mutations
Mini-Tn10dTet transposon insertions were used to identify mutations responsible for protamine resistance in six mutants with different growth rates all slower than that of the parental strain. The six selected strains all carried the TetR marker at different positions on the chromosome. The remaining mutants were linked to one of these six TetR markers, indicating that all the 23 mutations were located in any one of six areas of the chromosome. By performing an arbitrarily primed PCR out from the transposon followed by DNA sequencing of the amplified area, the transposon insertion points were identified in the genes yaiU, narK, stfG, STM3940 and ybjE and between yigC and fre [ Figure S1a , available as Supplementary data at JAC Online (http://jac.oxfordjournals.org/ )]. These genes are all located in close proximity to genes involved in haem biosynthesis or respiration ( Figure S1a ). Mutations in respiratory genes are common in SCVs and could explain many of the phenotypic traits seen in the protamine-resistant mutants. We therefore PCR amplified and sequenced genes with predicted functions in respiration and maintenance of the electrochemical gradient and could in this way identify the mutations in 22 of the mutants (Table 1) . Nine mutants carried mutations in hemA, of which three were deletions, one was a nonsense mutation and five were missense mutations. Five mutants had mutations in hemL; three strains carried missense mutations and two strains a single base pair insertion. Three strains were mutated in hemC (all missense mutations) and two strains harboured deletions of hemB and the upstream and downstream genes prpE and yaiU. All of the above genes are directly involved in the biosynthesis of haem [ Figure S1b , available as Supplementary data at JAC Online Protamine resistance in Salmonella Typhimurium LT2 879 JAC (http://jac.oxfordjournals.org/)]. 31 Of the remaining mutants, three strains carried nonsense mutations in cydC, which encodes the membrane/ATP-binding component of a cysteine/glutathione ABC transporter, and one mapped close to the transposon between yigC and fre (mutation not identified).
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Characterization of mutants
The MIC of protamine needed to inhibit growth varied between the mutants and ranged from 125 to .2000 mg/L, compared with 95 mg/L for the wild-type strain ( Table 1 ). The hemL and cydC mutants were less resistant than those carrying mutations in hemA, hemC and hemB (MIC 250 mg/L compared with 500 to .2000 mg/L). One mutant in particular, DA10887 (hemC T241P), was highly resistant to protamine and survived at all concentrations tested. Two independently constructed mutants with MudJ insertions in hemB and hemG, respectively (DA15245 and DA15248), were also more resistant to protamine than the wildtype strain (Table 1) . When spotted or streaked on agarose plates supplemented with protamine, all mutants could also grow and form colonies on higher protamine concentrations than the wild-type strain (data not shown). The cysG gene product is involved in several catalytic steps in the synthesis of sirohaem and cobalamin from uroporphyrinogen III, an intermediate in the haem biosynthetic pathway. 34 A constructed cysG mutant (cysG1510::Tn10, DA15260) showed no growth defects on agar plates and was not resistant to protamine ( Table 1 ), indicating that defects in this branch of the pathway are not involved in the observed resistance ( Figure S1b) .
For the mutants isolated in this study, there was a correlation between growth rate and level of protamine resistance [ Figure S2 , available as Supplementary data at JAC Online (http:// jac.oxfordjournals.org/)]. Generally, the slower the growth rate, the higher the resistance. However, protamine susceptibility was also determined for two slow-growing strains with mutations in fmt and rplQ, two genes with no known function in respiration (DA8326 and DA14505, respectively). These strains were as susceptible to protamine as the wild-type strain, indicating that slow growth alone is not sufficient to cause protamine resistance (Table 1) .
Several previous studies have reported difficulties when measuring the MIC of protamine in liquid broth because the positively charged protamine is prone to interact with components of the broth and cause precipitation. 7, 8, 11 To assess these concerns we compared the precipitation of protamine in LB, TSB and IsoSensitest broth. With Iso-Sensitest broth, a faint turbidity was observed in the tubes with the highest concentrations of protamine. This was much less pronounced than that seen in LB or TSB (data not shown). It is still possible that the MIC is slightly overestimated due to precipitation of protamine; however, this should affect all strains in the same way, and all mutants were significantly more resistant than the wild-type strain. It has also been observed that protamine causes clumping of cells, but in our experiments this was not observed when examining protamine-treated cells under the microscope. 8, 9 ALA and haemin complementation studies
The hemA and hemL gene products are involved in the early steps of haem biosynthesis where glutamate is converted into ALA. 35, 36 Supplementation with extracellular ALA is expected to compensate for the defects caused by these mutations and restore protamine susceptibility in the mutants. Therefore, complementation studies with ALA were performed for representative strains with mutations in the following genes: hemL (DA10886); hemA (DA10888); cysG (DA15260); hemA and cysG (DA15055); hemC (DA10887); and hemG (DA15248).
When supplemented with ALA, growth of the examined hemL and hemA mutants was improved, with a concomitant loss of the protamine resistance phenotype (i.e. susceptibility was restored to that of the wild-type strain). The results are presented in Table 2 . The protamine susceptibility of the wild-type strain (MIC 125 mg/L in these experiments, compared with 95 mg/L when averaging all MIC assays) and the cysG mutant was similar in medium with and without ALA. The hemC and hemG mutants (involved in biosynthetic steps downstream of ALA completion) were not complemented by ALA and retained the protamine resistance phenotype, as expected ( Table 2 ).
Given that mutations in several genes involved in haem biosynthesis resulted in protamine resistance and a slow growth Pränting and Andersson phenotype, it seemed likely that the observed protamine resistance was caused by lack of the end product haem rather than by the lack of intermediates of the haem biosynthetic pathway. To confirm this idea we determined the growth and resistance pattern of a hemA mutant (V45G) in the presence of haemin. Since Salmonella Typhimurium LT2 is not naturally permeable to haemin, this hem mutation was moved into a haemin-permeable background by transduction. The resulting strain was more susceptible to protamine than the original mutant, but was still more resistant than the isogenic, haeminpermeable control. The strain was able to grow better than the parental mutant when supplemented with haemin in a disc on LA, but still had a growth defect compared with the wild-type strain (data not shown). As can be seen in Table 2 , growth in the presence of haemin restored protamine susceptibility in the hem mutant to the level seen in the control, thus indicating that haem deficiency was responsible for the observed protamine resistance in the strains carrying hem mutations.
Fitness of protamine-resistant mutants
All of the protamine-resistant mutants showed a drastic reduction in growth, forming tiny colonies on LA plates after 24 or 48 h incubation. As a measure of fitness, the exponential growth rate relative to the wild-type strain was determined for the mutants. All of the examined mutants were significantly impaired in growth, with relative growth rates ranging from 0.25 to 0.85 as compared with that of the susceptible wild-type strain that was set to 1 ( Table 1) . The hemL and cydC mutants were more fit (relative growth rates 0.53-0.85) than mutants defective in other hem genes (relative growth rates 0.27 -0.39).
Apart from a reduction in the exponential growth rate, most of the examined mutants also had a substantially longer lag phase than the wild-type strain (data not shown).
Antibiotic susceptibility of protamine-resistant mutants
SCVs have been associated with infections that are persistent and difficult to treat. 17 -19 Although the parental strain is susceptible to a certain antibiotic, the SCVs often have a different resistance pattern. 17, 37, 38 In order to characterize the protamine-resistant mutants isolated in the present study, the susceptibility of a subset of the strains to commonly used antibiotics and the lipopeptide colistin was investigated using Etests. The resulting MICs are presented in Table 3 together with the MICs determined for the wild-type parental strain. All the examined mutant strains were resistant to aminoglycosides, in accordance with what has been observed in previous studies with SCVs. 17, 38, 39 The MICs of gentamicin and streptomycin for the mutants were increased 32-fold and 4-to 24-fold relative to the wild-type, respectively. The mutants were also less susceptible to colistin (3-to 4-fold increase in the MIC), with the exception of the hemL mutant (the cydC mutant was not tested). On the other hand, the examined mutants were generally more susceptible to chloramphenicol and nitrofurantoin, and all except the cydC mutant were more susceptible to ampicillin and tetracycline. Ciprofloxacin was equally active against all strains.
To further define the resistance phenotype, we investigated the time -kill kinetics of colistin, streptomycin, chloramphenicol and tetracycline for DA10887 (hemC T241P), DA10888 (hemA V45G) and DA6192 (wild-type). In Figure 1 , cell viability (as a percentage of the starting inocula) is plotted over time. As was seen in the Etest assay, both hem mutants were less susceptible to colistin (1 mg/L) and streptomycin (8 mg/L) than the wild-type strain. The growth curves of the mutants were similar both with and without antibiotics. In experiments with colistin and streptomycin both treated wild-type and mutant cells grew to 10 8 -10 9 cfu/mL in 24 h (data not shown). Chloramphenicol (6 mg/L) and tetracycline (3 mg/L) had a bacteriostatic effect on the hem mutants, while the wild-type strain, although affected, grew quite well in the presence of these antibiotics.
AMP susceptibility of protamine-resistant mutants
Given the low protamine susceptibility of several of the mutants, we wanted to examine if this resistance could protect from the killing effects of other types of AMPs. One hem mutant with high protamine resistance, DA10887 (hemC T241P), was chosen and subjected to various AMPs of different origin and mode of action. The MICs of each peptide are presented in Table 4 . In the MIC experiments, no cross-resistance to the tested peptides was observed for the protamine-resistant Protamine resistance in Salmonella Typhimurium LT2 881 JAC hemC mutant. In fact, the mutant was more susceptible than the wild-type strain to several peptides. The largest difference in resistance was for bleomycin, for which the mutant was three times more susceptible than the wild-type. However, the hemC mutant was killed at a slower rate and to a lesser extent upon both lactoferricin and HNP-1 treatment compared with the wild-type strain (Figure 2a and b, respectively) . After 3 h of lactoferricin treatment, the percentage of viable cells remaining of the initial inocula was 100%, 15% and 8% for the mutant in 2.5, 5 and 10 mg/L lactoferricin, respectively. During the same time, the wild-type decreased to 7%, 0.5% and 0.005% of the initial inocula. Approximately 60% of the mutant cells were viable after a 5 h treatment with 100 mg/L HNP-1, compared with only 0.1% of the wild-type cells.
Instability and compensatory evolution in protamineresistant mutants
The slow growth phenotype of some of the mutants was not stable. Occasionally during overnight growth on LA, one or a few large colonies would appear among the slow-growing mutants. This was observed in particular for hemC mutants Pränting and Andersson and certain hemA mutants. To examine the phenotypic stability in detail, four low-fitness mutants with different mutations (DA10886, hemL T297P; DA10887, hemC T241P; DA10888, hemA V45G; DA10891, hemB deletion) were subjected to compensatory evolution by serial passage through population bottlenecks. Fitness was measured, relative to the wild-type strain, for all compensated lineages (Figure 3 ). For strains DA10886 and DA10888 only 4/10 lineages compensated within 370 generations of growth and no compensation was observed for strain DA10891 (Table 5) . Interestingly, all 10 lineages of strain DA10887 had compensated within 70 generations of growth and most compensated within 30 generations of growth (four passages, Table 5 ). The majority of these lineages still grew significantly more slowly than the wild-type strain (Figure 3 ). The hemL, hemA and hemC genes from a set of the respective compensated mutants were sequenced to identify intragenic compensatory mutations (Table 5 ). In all hemL lineages, the proline at position 297 of the protein in the resistant strain had been replaced by a serine. Three of the compensated hemA lineages were true genetic revertants. The compensatory mutation was not identified for the fourth lineage. In one of the compensated hemC lineages, the proline at position 241 of the protein had been replaced by leucine and in another by asparagine. One hemC lineage compensated in two steps; first to a growth rate of 0.54, then to 0.85 in 14 and 41 generations, respectively. The intermediately fit strain had no secondary mutations in hemC, while the fast-growing strain carried a histidine at amino acid position 241. In two strains, there was double sequence at the position of the compensatory mutation, indicating the presence of a duplication that included the hemC gene.
To address whether hemC mutants were generally unstable, two additional strains with mutations in hemC (DA11803, Q287P; DA11805, V249E) were evolved in a subsequent cycling experiment. These strains compensated even more quickly and all lineages formed normal or near to normal sized colonies within only 30 generations of growth (data not shown). In general, compensation of growth defects led to a loss of protamine resistance, as shown by MIC determinations ( Table 5 ). The lineage of strain DA10887 that increased the least in fitness partly retained the resistance phenotype and could survive a protamine concentration of 375 mg/L.
Discussion
Protamines are cationic peptides with antimicrobial activity that have been used as model peptides in studies of more easily inactivated or expensive AMPs. The mechanism of bacterial killing by protamine is not fully understood, but is thought to involve initial contact through electrostatic interactions between the positively charged peptide and the negatively charged bacterial envelope, followed by a general disruption of the membrane, leakage of K þ , ATP and other cellular components, and inhibition of metabolic processes, including protein synthesis. 40 -42 In this study, spontaneous, protamine-resistant mutants of Salmonella Typhimurium LT2 were isolated at a rate of 2.3Â10
27
/cell/generation. In general, the strains with the slowest growth rates were more resistant to protamine. It should, however, be noted that slow growth per se did not cause protamine resistance, since slow-growing strains with mutations in genes with no known Protamine resistance in Salmonella Typhimurium LT2 883 JAC involvement in respiration (e.g. fmt and rplQ mutants) were not resistant to protamine. The mutations responsible for protamine resistance were identified in 22 of the 23 mutants. Nineteen mutants carried mutations in genes involved in four different steps of haem biosynthesis. These mutations were found at 14 different locations in the genes. The variety of different mutations confirms the presence of a large mutational target and explains the relatively high mutation rate. Furthermore, it indicates that it is the lack of the end product of the pathway, haem, that causes resistance and not the individual proteins or metabolic intermediates of the pathway. In bacteria, haem is involved in multiple cellular functions including respiration and regulation of gene expression. Haem serves as cofactor for many cytochromes and catalases, and sirohaem and cobalamin production is dependent on intermediates of the haem biosynthetic pathway. 31, 34, 35, 43 Mutations in the different hem genes lead to defects in electron transport and respiration. This in turn causes slow growth by reducing the amount of ATP available for metabolism and leads to a decreased transmembrane potential, reducing the affinity for and uptake of cationic compounds, explaining the observed protamine resistance. 17 Three of the protamine-resistant mutants carried a nonsense mutation at the same position of cydC. These mutants had a growth rate that was 15% lower than that of the wild-type strain and were among the least resistant mutants. In Escherichia coli, cydC encodes a subunit of an ATP-binding cassette transporter (CydDC). 32, 33 The sequence similarity of the E. coli and Salmonella Typhimurium LT2 cydC genes is 75% at the nucleotide level, and the protein probably has a similar function in the two strains. Goldman et al. 44 found the periplasm of an E. coli cydC mutant to be more oxidized than that of the wildtype strain and it was suggested that the CydDC transporter maintains redox balance by exporting reducing molecules to the periplasm. It was later demonstrated that cysteine and the antioxidant glutathione are substrates for the transporter. 32, 33 The lowered reducing power in the cydC mutants is thought to affect several important functions, including assembly of c-type cytochromes and functioning periplasmic cytochrome b.
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These defects will in turn affect several cellular functions including electron transport, which would explain the lower protamine susceptibility. The less severe phenotype changes in these mutants might reflect redundancy in the regulation of redox homeostasis.
The hemA and hemL gene products are involved in production of 5-ALA, an intermediate in the haem biosynthetic pathway. 35 Protamine resistance and growth defects of the examined hemL and hemA mutants could be reversed by addition of ALA to the growth medium, establishing the connection between defects in ALA production and the resistance phenotype of these mutants. It has been observed that ALA can be produced non-enzymatically in a hemL-independent fashion, which may explain the somewhat higher fitness observed for the hemL mutants compared with other hem mutants. 36, 45 An alternative explanation would be that the defective enzyme retains residual activity, allowing a low level of ALA production. Furthermore, hemA is the first gene in an operon and expression of the downstream genes might, due to polarity effects, be altered in the 
Pränting and Andersson
hemA mutants, resulting in fitness costs unrelated to the production of ALA. As expected, ALA supplementation had no effect on hemC and hemG mutants impaired in haem biosynthetic reactions subsequent to completion of ALA synthesis. In addition, a mutant defective in the first steps of sirohaem and cobalamin synthesis was not resistant to protamine in either the presence or absence of ALA, enabling us to rule out involvement of these two products in protamine resistance. Protamine susceptibility of a haemin-permeable hemA mutant could be reversed by exogenous haemin, further indicating that haem deficiency caused the resistance phenotype.
Mutants deficient in respiratory genes have been isolated from clinical specimens from various sites of the body and are being increasingly recognized as a major contributor to persistent and recurrent diseases such as osteomyelitis, cystic fibrosis and foreign body-related infections. 17, 19 These SCVs have an improved capacity to survive within cells and are more resistant to many antimicrobials, including aminoglycosides. 20, 38, 46, 47 Similar to clinical SCVs, all examined protamine-resistant mutants were less susceptible to aminoglycosides than the parental strain, irrespective of whether they carried hem or cydC mutations. Aminoglycoside transport over the bacterial membrane is dependent on a charge differential across the membrane, formed during electron transport and respiration. 19, 39 Thus, the respiratory defects of the mutants interrupt uptake and function of the antibiotic. The mutants were also less susceptible to the lipopeptide antibiotic colistin. Colistin activity is dependent on electrostatic interactions between the antibiotic and the negatively charged bacterial membrane, and, following the same reasoning as above, the respiratory defects of the mutants probably produce changes in the bacteria that reduce this interaction. 48 It has been previously observed that SCVs of S. aureus with different auxotrophisms are resistant to the AMP lactoferricin B. 49 Similarly, we found a Salmonella Typhimurium LT2 SCV (hemC T241P) to be less susceptible to this peptide. Samuelsen et al. 49 suggested that lactoferricin resistance was caused by a reduced metabolic activity rather than by decreased membrane interaction and uptake, based on the observation that labelled peptide was efficiently internalized by the SCV. The examined hemC mutant was also less susceptible to the human defensin HNP-1. Together with HNP-2 and 3, this peptide accounts for 5% of the human neutrophil proteins. 2, 30 Other immune cells, e.g. T cells, also express HNP-1, and it seems likely that resistance could facilitate bacterial survival in the human body. 2 That is, respiratory defects of SCVs can increase resistance to several antimicrobial agents, including peptides present in the human body, and probably does this through several different mechanisms.
Clinically isolated SCVs are often described as unstable, frequently reverting to a normal colony phenotype. Generally, protamine resistance conferred a high fitness cost displayed as a reduced growth rate. The majority of the mutants appeared to be phenotypically stable, but occasionally certain mutants re-established fast growth. For some mutant strains it was possible to select variants with increased fitness and second-site mutations by serial passage of the mutants in the absence of selection. For the examined hemA and hemL mutants only a few of the individual lineages compensated and a substantial fraction of these were genetic revertants. No compensation was observed for a strain with a deletion of hemB, whereas, in contrast, all lineages of strain DA10887 (hemC, T241P) compensated rapidly. The growth rates of these lineages were significantly lower than that of the wild-type strain, indicating that they did not revert back to the parental genotype. When the hemC gene of these mutants was sequenced, some strains were found to have a double DNA sequence at specific positions in the gene, indicating the presence of a duplication and subsequent mutational divergence. This in turn provides a possible explanation for the fast compensation of all DA10887 lineages. The hemC gene is located between two rRNA operons in an area of the chromosome known to undergo frequent duplications (sequence repeats provide substrate for duplications), which may play a role in the fast compensation in these strains. 50 If so, this would provide a novel mechanism for the reported phenotypic instability of many SCVs. The potential occurrence of gene duplications in these strains is currently under investigation.
In the present study, all isolated protamine-resistant mutants have the typical characteristics of SCVs. They grow slowly and carry resistance mutations in genes associated with redox reactions and respiration, are resistant to aminoglycosides, other antibiotics and peptides, and some are also genetically unstable. A large fitness cost, as observed for the mutants in this study, would normally imply a competitive disadvantage in the absence of selective pressure, and it is expected that such strains would be outcompeted by faster growing strains. However, SCVs are frequently recovered from patients and have been suggested to be an important part of the disease progression and survival in the host for intracellular pathogens. Thus, the low fitness observed might actually provide a survival advantage in this case. Spontaneously formed SCVs of Salmonella have only been isolated and characterized in a few studies, but, as emphasized by Proctor and co-workers in their studies of SCVs in S. aureus, certain AMPs in the body might select for or stabilize the SCV phenotype. 17, 18, 20 Formation of SCVs could be a way for the bacteria to avoid killing by certain AMPs, and could be a potential problem for the use of pharmaceuticals based on AMP structures whose mode of action is based on an energized bacterial membrane or actively growing bacteria.
